Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with.
TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response to
Investegate announcements from Ultimovacs ASA, Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting
Oslo, March 9, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will present data on the preclinical evaluation of the